Selective transgene expression for detection and elimination of contaminating carcinoma cells in hematopoietic stem cell sources

Journal of Clinical Investigation

Volumn 98, Issue 11, 1996, Pages 2539-2548

  Chen, Ling ^a   Pulsipher, Michael ^a   Chen, Dongshu ^a   Sieff, Colin ^a   Elias, Anthony ^a   Fine, Howard A ^a   Kufe, Donald W ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

adenovirus; bone marrow; breast cancer; gene therapy; thymidine kinase

Indexed keywords

CD34 ANTIGEN; GANCICLOVIR; INTEGRIN; VIRUS VECTOR;

ADENOVIRUS; ARTICLE; BREAST CANCER; CARCINOMA CELL; CELL KILLING; CELL SPECIFICITY; CYTOMEGALOVIRUS; GENE EXPRESSION; GENE THERAPY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; SIGNAL TRANSDUCTION; STEM CELL; VIRUS REPLICATION;

EID: 0029807602     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119072     Document Type: Article

References (46)

1. Peters, W.P., E.J. Shpall, R.B. Jones, G.A. Olsen, R.C. Bast, J.P. Gockerman, and J.O. Moore. 1988. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J. Clin. Oncol. 6:1368-1376.
2. Kennedy, M.J., R.A. Beveridge, S.D. Rowley, G.B. Gordon, M.D. Abeloff, and N.E. Davidson. 1991. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J. Natl. Cancer Inst. 83:920-926.
3. Antman, K., L. Ayash, A. Elias, C. Wheeler, M. Hunt, J.P. Eder, B.A. Teicher, J. Critchlow, J. Bibbo, L.E. Schnipper, et al. 1992. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J. Clin. Oncol. 10:102-110.
4. Peters, W.P., M. Ross, J.J. Vredenburgh, B. Meisenberg, L.B. Marks, E. Winer, J. Kurtzberg, R.C. Bast, Jr., R. Jones, E. Shpall, et al. 1993. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J. Clin. Oncol. 11:1132-1143.
5. Ross, A.A., B.W. Cooper, H.M. Lazarus, W. Mackay, T.J. Moss, N. Ciobanu, M.S. Tallman, M.J. Kennedy, N.E. Davidson, D. Sweet, et al. 1993. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood. 82:2605-1210.
6. Cote, R.J., P.P. Rosen, M.L. Lesser, L.J. Old, and M.P. Osborne. 1991. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J. Clin. Oncol. 9:1749-1756.
7. Diel, I.J., M. Kaufmann, R. Goerner, S.D. Costa, S. Kaul, and G. Bastert. 1992. Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. J. Clin. Oncol. 10:1234-1539.
8. Molino, A., M. Colombatti, F. Bonetti, M. Zardini, F. Pasini, A. Perini, G. Pelosi, G. Tridente, D. Veneri, and G.L. Cetto. 1991. A comparative analysis of three different techniques for the detection of breast cancer cells in bone marrow. Cancer. 67:1033-1036.
9. Simpson, S.J., M. Vachula, M.J. Kennedy, H. Kaizer, J.S. Coon, R. Ghalie, S. Williams, and D. Van Epps. 1995. Detection of tumor cells in the bone marrow, peripheral blood, and apheresis products of breast cancer patients using flow cytometry. Exp. Hematol. 23:1062-1068.
10. Datta, Y.H., P.T. Adams, W.R. Drobyski,. S.P. Ethier, V.H. Terry, and M.S. Roth. 1994. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J. Clin. Oncol. 12:475-482.
11. Gerhard, M., H. Juhl, H. Kalthoff, H.W. Schreiber, C. Wagener, and M. Neumaier. 1994. Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J. Clin. Oncol. 12:725-729.
12. Anderson, I.C., E.J. Shpall, D.S. Leslie, K. Nustad, J. Ugelstad, W.P. Peters, and R.C. Bast, Jr. 1989. Elimination of malignant clonogenic breast cancer cells from human bone marrow. Cancer Res. 49:4659-4664.
13. Tondini, C., S.A. Pap, D.F. Hayes, A.D. Elias, and D.W. Kufe. 1990. Evaluation of monoclonal antibody DF3 conjugated wtih ricin as a specific immunotoxin for in vitro purging of human bone marrow. Cancer Res. 50:1170-1175.
14. Shpall, E.J., R.C. Bast, Jr., W.T. Joines, R.B. Jones, I. Anderson, C. Johnston, S. Eggleston, M. Tepperberg, S. Edwards, and W.P. Peters. 1991. Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation. Bone Marrow Transplant. 7:145-151.
15. Shpall, E.J., R.B. Jones, R.C. Bast, Jr., G.L. Rosner, R. Vandermark, M. Ross, M.L. Affronti, C. Johnston, S. Eggleston, M. Tepperburg, et al. 1991. 4-hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. J. Clin. Oncol. 9:85-93.
16. Myklebust, A.T., A. Godal, S. Juell, A. Pharo, and O. Fodstad. 1994. Comparison of two antibody-based methods for elimination of breast cancer cells from human bone marrow. Cancer Res. 54:209-214.
17. Passos-Coelho, J., A.A. Ross, J.M. Davis, A.M. Huelskamp, B. Clarke, S.J. Noga, N.E. Davidson, and M.J. Kennedy. 1994. Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: effect of ex vivo purging with 4-hydroperoxycyclophosphamide. Cancer Res. 54:2366-2371.
18. Graham, F.L., J. Smiley, W.C. Russel, and R. Nairn. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36:59-72.
19. Manome, Y., M. Abe, M.F. Hagen, H.A. Fine, and D.W. Kufe. 1994. Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir. Cancer Res. 54:5408-5413.
20. Chen, L., D. Chen, Y. Manome, Y. Dong, H.A. Fine, and D.W. Kufe. 1995. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J. Clin. Invest. 96: 2775-2782.
21. Kufe, D., G. Inghirami, M. Abe, D. Hayes, H. Justi-Wheeler, and J. Schlom. 1984. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma. 3:223-232.
22. Friedman, E.L., D.G. Hayes, and D.W. Kufe. 1986. Reactivity of monoclonal antibody DF3 with a high molecular weight antigen expressed in human ovarian carcinomas. Cancer Res. 46:5189-5194.
23. Maimonis, P., D. Hayes, C. O'Hara, and D. Kufe. 1990. Detection and characterization of a high molecular weight lung carcinoma-associated antigen. Cancer Res. 50:6738-6743.
24. Sutherland, H.J., P.M. Lansdorp, D.H. Henkelman, A.C. Eaves, and C.J. Eaves. 1990. Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers. Proc. Natl. Acad. Sci. USA. 87:3584-3588.
25. 5 monoclonal antibodies. J. Cell Sci. 105:101-111.
26. Herz, J., and R.D. Gerard. 1993. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc. Natl. Acad. Sci. USA. 90:2812-2816.
27. Abe, M., and D. Kufe. 1993. Characterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUC1) gene. Proc. Natl. Acad. Sci. USA. 90:282-286.
28. Graham, F.L., and L. Prevec. 1991. Manipulation of adenovirus vectors. In Methods in Molecular Biology: Gene Transfer and Expression Protocols. E.J. Murray, editor. The Humana Press, Inc., Clifton, N.J. 109-128.
29. Jain, V.K., and I.T. Magrath. 1991. A chemiluminescent assay for quantitation of beta-galactosidase in the femtogram range: application to quantitation of beta-galactosidase in lacZ-transfected cells. Anal. Biochem. 199:119-124.
30. Nolan, G.P., S. Fiering, J.F. Nicolas, and L.A. Herzenberg. 1988. Fluorescence-activated cell analysis and sorting of viable mammalian cells based on beta-D-galactosidase activity after transduction of Escherichia coli lacZ. Proc. Natl. Acad. Sci. USA. 85:2603-2607.
31. Taswell, C. 1981. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J. Immunol. 126:1614-1619.
32. Nolta, J.A., E.M. Smogorzewska, and D.B. Kohn. 1995. Analysis of optimal conditions for retroviral-mediated transduction of primitive human hematopoietic cells. Blood. 86:101-110.
33. Zhang, W.W., P.E. Koch, and J.A. Roth. 1995. Detection of wild-type contamination in a recombinant adenoviral preparation by PCR. Biotechniques. 18:444-447.
34. Steel, R.G.D., and J.H. Torrie. 1960. Principles and Procedures of Statistics with Special Reference to the Biological Sciences. McGraw-Hill Book Co. New York. 1-481.
35. Mathias, P., T. Wickham, M. Moore, and G. Nemerow. 1994. Multiple adenovirus serotypes use alpha v integrins for infection. J. Virol. 68:6811-6814.
36. Wickham, T.J., P. Mathias, D.A. Cheresh, and G.R. Nemerow. 1993. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell. 73:309-319.
37. Wu, G. Y., and C.H. Wu. 1988. Receptor-mediated gene delivery and expression in vivo. J. Biol. Chem. 263:14621-14624.
38. Wu, G.Y., J.M. Wilson, F. Shalaby, M. Grossman, D.A. Shafritz, and C.H. Wu. 1991. Receptor-mediated gene delivery in vivo. Partial correction of genetic analbuminemia in Nagase rats. J. Biol. Chem. 266:14338-14342.
39. Nabel, E.G., G. Plautz, and G.J. Nabel. 1990. Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science (Wash. DC). 249:1285-1288.
40. Nabel, E.G., D. Gordon, Z.Y. Yang, L. Xu, H. San, G.E. Plautz, B.Y. Wu, X. Gao, L. Huang, and G.J. Nabel. 1992. Gene transfer in vivo with DNA-liposome complexes: lack of autoimmunity and gonadal localization. Hum. Gene Ther. 3:649-656.
41. Seth, P., U. Brinkmann, G.N. Schwartz, D. Katayose, R. Gress, I. Pastan, and K. Cowan. 1996. Adenovirus-mediated gene transfer to human breast tumor cells: an approach for cancer gene therapy and hone marrow purging. Cancer Res. 56:1346-1351.
42. Vile, R.G., and I.R. Hart. 1993. In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res. 53:962-967.
43. Vile, R.G., and I.R. Hart. 1993. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res. 53:3860-3864.
44. Huber, B.E., C.A. Richards, and T.A. Krenitsky. 1991. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc. Natl. Acad. Sci. USA. 88:8039-8043.
45. Harris, J.D., A.A. Gutierrez, H.C. Hurst, K. Sikora, and N.R. Lemoine. 1994. Gene therapy for cancer using tumor-specific prodrug activation. Gene Therapy. 1:170-175.
46. s adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells. Proc. Natl. Acad. Sci. USA. 92: 11024-11028.